George Jean Kahaly, M.D., Ph.D.
Dr. Kahaly is currently the Professor of Medicine and Endocrinology / Metabolism and is chief of the endocrine outpatient clinic at the Gutenberg University Medical Center, Mainz, Germany. Dr. Kahaly directs the Molecular Thyroid Research Laboratory and has authored 214 original papers and reviews, covering both clinical and experimental aspects of endocrine autoimmunity, immunogenetics of thyroid and polyglandular autoimmunity, as well as cardiovascular involvement of metabolic disorders. Dr. Kahaly organized and co-chaired numerous international scientific meetings in the USA, Europe, and in Asia dealing with molecular and endocrine autoimmunity.
Dr. Kahaly was one of two co-principal investigators of the phase 3 OPTIC trial, a multi-center international clinical trial (23 centers), the data of which were used by the U.S. FDA as the basis for approving Tepezza (teprotumumab) as a new treatment for thyroid eye disease (TED). The FDA approval of Tepezza was granted in January of 2020. The results from the trial were recently published in the New England Journal of Medicine.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.